Loading…

Dihydropyridines Potentiate ATP-Induced Currents Mediated by the Full-Length Human P2X5 Receptor

The P2X5 receptor, an ATP-gated cation channel, is believed to be involved in tumor development, inflammatory bone loss and inflammasome activation after bacterial infection. Therefore, it is a worthwhile pharmacological target to treat the corresponding diseases, especially in minority populations...

Full description

Saved in:
Bibliographic Details
Published in:Molecules (Basel, Switzerland) Switzerland), 2022-03, Vol.27 (6), p.1846
Main Authors: Schiller, Ida C, Jacobson, Kenneth A, Wen, Zhiwei, Malisetty, Aparna, Schmalzing, Günther, Markwardt, Fritz
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c493t-bfc088c64b0c0c3c9f97ea785634238cd2ccc12c8ccb1cb412125e8ce5d355b43
cites cdi_FETCH-LOGICAL-c493t-bfc088c64b0c0c3c9f97ea785634238cd2ccc12c8ccb1cb412125e8ce5d355b43
container_end_page
container_issue 6
container_start_page 1846
container_title Molecules (Basel, Switzerland)
container_volume 27
creator Schiller, Ida C
Jacobson, Kenneth A
Wen, Zhiwei
Malisetty, Aparna
Schmalzing, Günther
Markwardt, Fritz
description The P2X5 receptor, an ATP-gated cation channel, is believed to be involved in tumor development, inflammatory bone loss and inflammasome activation after bacterial infection. Therefore, it is a worthwhile pharmacological target to treat the corresponding diseases, especially in minority populations that have a gene variant coding for functional homotrimeric P2X5 channels. Here, we investigated the effects of dihydropyridines on the human full-length P2X5 receptor (hP2X5 ) heterologously expressed in oocytes using the two-microelectrode voltage clamp method. Agonist dependency, kinetics and permeation behavior, including Cl permeability, were similar to hP2X5 expressed in HEK293 or 1321N1 cells. Additionally, 1,4-dihydropyridines have been shown to interact with various other purinergic receptors, and we have examined them as potential hP2X5 modulators. Of seven commercially available and four newly synthesized dihydropyridines tested at hP2X5 , only amlodipine exerted an inhibitory effect, but only at a high concentration of 300 µM. Isradipine and-even more-nimodipine stimulated ATP-induced currents in the low micromolar range. We conclude that common dihydropyridines or four new derivatives of amlodipine are not suitable as hP2X5 antagonists, but amlodipine might serve as a lead for future synthesis to increase its affinity. Furthermore, a side effect of nimodipine therapy could be a stimulatory effect on inflammatory processes.
doi_str_mv 10.3390/molecules27061846
format article
fullrecord <record><control><sourceid>proquest_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_242ef63c23714d6d821113a9ea905ec5</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><doaj_id>oai_doaj_org_article_242ef63c23714d6d821113a9ea905ec5</doaj_id><sourcerecordid>2644017230</sourcerecordid><originalsourceid>FETCH-LOGICAL-c493t-bfc088c64b0c0c3c9f97ea785634238cd2ccc12c8ccb1cb412125e8ce5d355b43</originalsourceid><addsrcrecordid>eNplkk1v00AQhi0EoqXwA7iglbhwMey31xekKlAaKYgIFYnbsp4dJxvZ3rBrI-Xf45BStXCa0cw7j-arKF4y-laImr7rY4cwdZh5RTUzUj8qzpnktBRU1o_v-WfFs5x3lHImmXpanAklhOK0Pi9-fAjbg09xf0jBhwEzWccRhzG4EcnlzbpcDn4C9GQxpTTHM_mM_pj0pDmQcYvkauq6coXDZtyS66l3A1nz74p8RcD9GNPz4knruowvbu1F8e3q483iulx9-bRcXK5KkLUYy6YFagxo2VCgIKBu6wpdZZQWkgsDngMA42AAGgaNZJxxhQZQeaFUI8VFsTxxfXQ7u0-hd-lgowv2TyCmjXVpDNCh5ZJjqwVwUTHptTecMSZcja6mCkHNrPcn1n5qevQwz51c9wD6MDOErd3EX9bU0uhKz4A3t4AUf06YR9uHDNh1bsA4Zcu1lJRVXNBZ-vof6S5OaZhXdVRxpSRnRyA7qSDFnBO2d80wao-_YP_7hbnm1f0p7ir-Hl_8Bophsfk</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2642554216</pqid></control><display><type>article</type><title>Dihydropyridines Potentiate ATP-Induced Currents Mediated by the Full-Length Human P2X5 Receptor</title><source>Open Access: PubMed Central</source><source>Publicly Available Content Database</source><creator>Schiller, Ida C ; Jacobson, Kenneth A ; Wen, Zhiwei ; Malisetty, Aparna ; Schmalzing, Günther ; Markwardt, Fritz</creator><creatorcontrib>Schiller, Ida C ; Jacobson, Kenneth A ; Wen, Zhiwei ; Malisetty, Aparna ; Schmalzing, Günther ; Markwardt, Fritz</creatorcontrib><description>The P2X5 receptor, an ATP-gated cation channel, is believed to be involved in tumor development, inflammatory bone loss and inflammasome activation after bacterial infection. Therefore, it is a worthwhile pharmacological target to treat the corresponding diseases, especially in minority populations that have a gene variant coding for functional homotrimeric P2X5 channels. Here, we investigated the effects of dihydropyridines on the human full-length P2X5 receptor (hP2X5 ) heterologously expressed in oocytes using the two-microelectrode voltage clamp method. Agonist dependency, kinetics and permeation behavior, including Cl permeability, were similar to hP2X5 expressed in HEK293 or 1321N1 cells. Additionally, 1,4-dihydropyridines have been shown to interact with various other purinergic receptors, and we have examined them as potential hP2X5 modulators. Of seven commercially available and four newly synthesized dihydropyridines tested at hP2X5 , only amlodipine exerted an inhibitory effect, but only at a high concentration of 300 µM. Isradipine and-even more-nimodipine stimulated ATP-induced currents in the low micromolar range. We conclude that common dihydropyridines or four new derivatives of amlodipine are not suitable as hP2X5 antagonists, but amlodipine might serve as a lead for future synthesis to increase its affinity. Furthermore, a side effect of nimodipine therapy could be a stimulatory effect on inflammatory processes.</description><identifier>ISSN: 1420-3049</identifier><identifier>EISSN: 1420-3049</identifier><identifier>DOI: 10.3390/molecules27061846</identifier><identifier>PMID: 35335209</identifier><language>eng</language><publisher>Switzerland: MDPI AG</publisher><subject>Adenosine Triphosphate - pharmacology ; Antagonists ; ATP ; Bacterial diseases ; Bone loss ; Bone tumors ; dihydropyridines ; Dihydropyridines - pharmacology ; Gametocytes ; HEK293 Cells ; Humans ; Inflammasomes ; Inflammation ; Kinetics ; Leukemia ; Ligands ; Microelectrodes ; Nimodipine ; Oocytes ; P2X5 receptor ; Patch-Clamp Techniques ; Permeability ; Purine receptors ; purinergic receptor ; Receptors, Purinergic ; voltage clamp ; Xenopus oocytes</subject><ispartof>Molecules (Basel, Switzerland), 2022-03, Vol.27 (6), p.1846</ispartof><rights>2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2022 by the authors. 2022</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c493t-bfc088c64b0c0c3c9f97ea785634238cd2ccc12c8ccb1cb412125e8ce5d355b43</citedby><cites>FETCH-LOGICAL-c493t-bfc088c64b0c0c3c9f97ea785634238cd2ccc12c8ccb1cb412125e8ce5d355b43</cites><orcidid>0000-0001-8104-1493 ; 0000-0002-0821-1369 ; 0000-0001-6761-2923</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.proquest.com/docview/2642554216/fulltextPDF?pq-origsite=primo$$EPDF$$P50$$Gproquest$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/2642554216?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,25753,27924,27925,37012,37013,44590,53791,53793,75126</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/35335209$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Schiller, Ida C</creatorcontrib><creatorcontrib>Jacobson, Kenneth A</creatorcontrib><creatorcontrib>Wen, Zhiwei</creatorcontrib><creatorcontrib>Malisetty, Aparna</creatorcontrib><creatorcontrib>Schmalzing, Günther</creatorcontrib><creatorcontrib>Markwardt, Fritz</creatorcontrib><title>Dihydropyridines Potentiate ATP-Induced Currents Mediated by the Full-Length Human P2X5 Receptor</title><title>Molecules (Basel, Switzerland)</title><addtitle>Molecules</addtitle><description>The P2X5 receptor, an ATP-gated cation channel, is believed to be involved in tumor development, inflammatory bone loss and inflammasome activation after bacterial infection. Therefore, it is a worthwhile pharmacological target to treat the corresponding diseases, especially in minority populations that have a gene variant coding for functional homotrimeric P2X5 channels. Here, we investigated the effects of dihydropyridines on the human full-length P2X5 receptor (hP2X5 ) heterologously expressed in oocytes using the two-microelectrode voltage clamp method. Agonist dependency, kinetics and permeation behavior, including Cl permeability, were similar to hP2X5 expressed in HEK293 or 1321N1 cells. Additionally, 1,4-dihydropyridines have been shown to interact with various other purinergic receptors, and we have examined them as potential hP2X5 modulators. Of seven commercially available and four newly synthesized dihydropyridines tested at hP2X5 , only amlodipine exerted an inhibitory effect, but only at a high concentration of 300 µM. Isradipine and-even more-nimodipine stimulated ATP-induced currents in the low micromolar range. We conclude that common dihydropyridines or four new derivatives of amlodipine are not suitable as hP2X5 antagonists, but amlodipine might serve as a lead for future synthesis to increase its affinity. Furthermore, a side effect of nimodipine therapy could be a stimulatory effect on inflammatory processes.</description><subject>Adenosine Triphosphate - pharmacology</subject><subject>Antagonists</subject><subject>ATP</subject><subject>Bacterial diseases</subject><subject>Bone loss</subject><subject>Bone tumors</subject><subject>dihydropyridines</subject><subject>Dihydropyridines - pharmacology</subject><subject>Gametocytes</subject><subject>HEK293 Cells</subject><subject>Humans</subject><subject>Inflammasomes</subject><subject>Inflammation</subject><subject>Kinetics</subject><subject>Leukemia</subject><subject>Ligands</subject><subject>Microelectrodes</subject><subject>Nimodipine</subject><subject>Oocytes</subject><subject>P2X5 receptor</subject><subject>Patch-Clamp Techniques</subject><subject>Permeability</subject><subject>Purine receptors</subject><subject>purinergic receptor</subject><subject>Receptors, Purinergic</subject><subject>voltage clamp</subject><subject>Xenopus oocytes</subject><issn>1420-3049</issn><issn>1420-3049</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>PIMPY</sourceid><sourceid>DOA</sourceid><recordid>eNplkk1v00AQhi0EoqXwA7iglbhwMey31xekKlAaKYgIFYnbsp4dJxvZ3rBrI-Xf45BStXCa0cw7j-arKF4y-laImr7rY4cwdZh5RTUzUj8qzpnktBRU1o_v-WfFs5x3lHImmXpanAklhOK0Pi9-fAjbg09xf0jBhwEzWccRhzG4EcnlzbpcDn4C9GQxpTTHM_mM_pj0pDmQcYvkauq6coXDZtyS66l3A1nz74p8RcD9GNPz4knruowvbu1F8e3q483iulx9-bRcXK5KkLUYy6YFagxo2VCgIKBu6wpdZZQWkgsDngMA42AAGgaNZJxxhQZQeaFUI8VFsTxxfXQ7u0-hd-lgowv2TyCmjXVpDNCh5ZJjqwVwUTHptTecMSZcja6mCkHNrPcn1n5qevQwz51c9wD6MDOErd3EX9bU0uhKz4A3t4AUf06YR9uHDNh1bsA4Zcu1lJRVXNBZ-vof6S5OaZhXdVRxpSRnRyA7qSDFnBO2d80wao-_YP_7hbnm1f0p7ir-Hl_8Bophsfk</recordid><startdate>20220311</startdate><enddate>20220311</enddate><creator>Schiller, Ida C</creator><creator>Jacobson, Kenneth A</creator><creator>Wen, Zhiwei</creator><creator>Malisetty, Aparna</creator><creator>Schmalzing, Günther</creator><creator>Markwardt, Fritz</creator><general>MDPI AG</general><general>MDPI</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope><orcidid>https://orcid.org/0000-0001-8104-1493</orcidid><orcidid>https://orcid.org/0000-0002-0821-1369</orcidid><orcidid>https://orcid.org/0000-0001-6761-2923</orcidid></search><sort><creationdate>20220311</creationdate><title>Dihydropyridines Potentiate ATP-Induced Currents Mediated by the Full-Length Human P2X5 Receptor</title><author>Schiller, Ida C ; Jacobson, Kenneth A ; Wen, Zhiwei ; Malisetty, Aparna ; Schmalzing, Günther ; Markwardt, Fritz</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c493t-bfc088c64b0c0c3c9f97ea785634238cd2ccc12c8ccb1cb412125e8ce5d355b43</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Adenosine Triphosphate - pharmacology</topic><topic>Antagonists</topic><topic>ATP</topic><topic>Bacterial diseases</topic><topic>Bone loss</topic><topic>Bone tumors</topic><topic>dihydropyridines</topic><topic>Dihydropyridines - pharmacology</topic><topic>Gametocytes</topic><topic>HEK293 Cells</topic><topic>Humans</topic><topic>Inflammasomes</topic><topic>Inflammation</topic><topic>Kinetics</topic><topic>Leukemia</topic><topic>Ligands</topic><topic>Microelectrodes</topic><topic>Nimodipine</topic><topic>Oocytes</topic><topic>P2X5 receptor</topic><topic>Patch-Clamp Techniques</topic><topic>Permeability</topic><topic>Purine receptors</topic><topic>purinergic receptor</topic><topic>Receptors, Purinergic</topic><topic>voltage clamp</topic><topic>Xenopus oocytes</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Schiller, Ida C</creatorcontrib><creatorcontrib>Jacobson, Kenneth A</creatorcontrib><creatorcontrib>Wen, Zhiwei</creatorcontrib><creatorcontrib>Malisetty, Aparna</creatorcontrib><creatorcontrib>Schmalzing, Günther</creatorcontrib><creatorcontrib>Markwardt, Fritz</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>AUTh Library subscriptions: ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>Molecules (Basel, Switzerland)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Schiller, Ida C</au><au>Jacobson, Kenneth A</au><au>Wen, Zhiwei</au><au>Malisetty, Aparna</au><au>Schmalzing, Günther</au><au>Markwardt, Fritz</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Dihydropyridines Potentiate ATP-Induced Currents Mediated by the Full-Length Human P2X5 Receptor</atitle><jtitle>Molecules (Basel, Switzerland)</jtitle><addtitle>Molecules</addtitle><date>2022-03-11</date><risdate>2022</risdate><volume>27</volume><issue>6</issue><spage>1846</spage><pages>1846-</pages><issn>1420-3049</issn><eissn>1420-3049</eissn><abstract>The P2X5 receptor, an ATP-gated cation channel, is believed to be involved in tumor development, inflammatory bone loss and inflammasome activation after bacterial infection. Therefore, it is a worthwhile pharmacological target to treat the corresponding diseases, especially in minority populations that have a gene variant coding for functional homotrimeric P2X5 channels. Here, we investigated the effects of dihydropyridines on the human full-length P2X5 receptor (hP2X5 ) heterologously expressed in oocytes using the two-microelectrode voltage clamp method. Agonist dependency, kinetics and permeation behavior, including Cl permeability, were similar to hP2X5 expressed in HEK293 or 1321N1 cells. Additionally, 1,4-dihydropyridines have been shown to interact with various other purinergic receptors, and we have examined them as potential hP2X5 modulators. Of seven commercially available and four newly synthesized dihydropyridines tested at hP2X5 , only amlodipine exerted an inhibitory effect, but only at a high concentration of 300 µM. Isradipine and-even more-nimodipine stimulated ATP-induced currents in the low micromolar range. We conclude that common dihydropyridines or four new derivatives of amlodipine are not suitable as hP2X5 antagonists, but amlodipine might serve as a lead for future synthesis to increase its affinity. Furthermore, a side effect of nimodipine therapy could be a stimulatory effect on inflammatory processes.</abstract><cop>Switzerland</cop><pub>MDPI AG</pub><pmid>35335209</pmid><doi>10.3390/molecules27061846</doi><orcidid>https://orcid.org/0000-0001-8104-1493</orcidid><orcidid>https://orcid.org/0000-0002-0821-1369</orcidid><orcidid>https://orcid.org/0000-0001-6761-2923</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1420-3049
ispartof Molecules (Basel, Switzerland), 2022-03, Vol.27 (6), p.1846
issn 1420-3049
1420-3049
language eng
recordid cdi_doaj_primary_oai_doaj_org_article_242ef63c23714d6d821113a9ea905ec5
source Open Access: PubMed Central; Publicly Available Content Database
subjects Adenosine Triphosphate - pharmacology
Antagonists
ATP
Bacterial diseases
Bone loss
Bone tumors
dihydropyridines
Dihydropyridines - pharmacology
Gametocytes
HEK293 Cells
Humans
Inflammasomes
Inflammation
Kinetics
Leukemia
Ligands
Microelectrodes
Nimodipine
Oocytes
P2X5 receptor
Patch-Clamp Techniques
Permeability
Purine receptors
purinergic receptor
Receptors, Purinergic
voltage clamp
Xenopus oocytes
title Dihydropyridines Potentiate ATP-Induced Currents Mediated by the Full-Length Human P2X5 Receptor
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-04T20%3A07%3A56IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Dihydropyridines%20Potentiate%20ATP-Induced%20Currents%20Mediated%20by%20the%20Full-Length%20Human%20P2X5%20Receptor&rft.jtitle=Molecules%20(Basel,%20Switzerland)&rft.au=Schiller,%20Ida%20C&rft.date=2022-03-11&rft.volume=27&rft.issue=6&rft.spage=1846&rft.pages=1846-&rft.issn=1420-3049&rft.eissn=1420-3049&rft_id=info:doi/10.3390/molecules27061846&rft_dat=%3Cproquest_doaj_%3E2644017230%3C/proquest_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c493t-bfc088c64b0c0c3c9f97ea785634238cd2ccc12c8ccb1cb412125e8ce5d355b43%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2642554216&rft_id=info:pmid/35335209&rfr_iscdi=true